Introduction
============

Ovarian tumors are a heterogeneous group of tumors including surface epithelial tumors, germ cell tumors, and sex cord stromal tumors. Borderline ovarian tumors (BOTs) comprise about 15%-20% of all epithelial ovarian malignancies, with an incidence of 1.8-4.8 per 100,000 women per year [@B1],[@B2]. Despite improvements in imaging techniques and identification of tumor markers, preoperative diagnosis of the malignant potential of ovarian tumors remains unreliable, and intra-operative pathological examination is irreplaceable [@B3]-[@B5]. Preference for frozen section (FS) diagnosis vs. paraffin section (PS) diagnosis of BOT differs from study to study. The sensitivity of FS ranges from 25% to 92% [@B3], [@B4], [@B6], [@B7], and specificity ranges from 60% to 99% [@B3], [@B4], [@B6]-[@B8]. Several authors have investigated the causes of low accuracy in FS examinations to identify BOTs and have defined various clinic-pathological features for prediction of misdiagnosis [@B9]-[@B16], but there is no consensus. The misdiagnosis by FS has a greater chance of harming patients. Hence, a correct and timely diagnosis of BOT is necessary.

The aims of our study are as follows: (1) to explore the accuracy of FS analysis of BOTs; (2) to determine the factors that affect the accuracy of diagnosis through FS; and (3) to assess the clinical outcomes of misdiagnosed BOT patients. We performed a retrospective study to establish our research aims, and we also performed a literature review and meta-analysis to confirm our research results. Based on our knowledge, this is the first meta-analysis to focus on the misdiagnosis factors of FS in BOTs patients.

Materials and methods
=====================

A retrospective study was performed with the ethical review board approval of Qilu Hospital. We identified all patients diagnosed with BOT through intra-operative FS or PS diagnosis at our institution from January 2005 to December 2015. BOT were classified as serous, mucinous, mixed, endometroid, clear cell, Brenner. Cases were excluded if: (1) there was no FS or PS diagnosis; (2) there were another primary malignancy; or (3) primary surgery was performed in another hospital. Medical records including clinical characteristics, operative reports, pathological and laboratory reports, and chemotherapy records were reviewed, and data were extracted. We also followed up with all patients, consulting about recurrence, death, and fertility outcome.

Fresh specimens were sent for intra-operative examination separated by five minutes, and one senior pathologist with more than five years\' experience reported on them within 30 minutes. Another pathologist reported on the paraffin sections. In another word, each case was reported by two different pathologists. The reports of FS and PS were divided into benign, borderline, and malignant. We also collected the information of specific final diagnosis such as micro-invasion, focal carcinoma, epithelial carcinoma, micro papillary and so on. Discrepancies included under-diagnosis, over-diagnosis. The standard type of care regarding BOT in our hospital are followed NCCN guidelines. Patients who desire to maintain their fertility may undergo surgery limited to a unilateral salpingo-oophorectomy (preserving the uterus, contralateral ovary, and contralateral Fallopian tube) with resection of residual disease. If the patient does not desire fertility sparing surgery, standard ovarian cancer debulking surgery and resection of residual disease are recommended.

Statistical analysis was performed using IBM SPSS Statistics 20.0 software. A *p* value of less than 0.05 was considered statistically significant. Univariate analysis was performed looking at predictors of accuracy on frozen sections which was two-tailed hypothesis. The accuracy, sensitivity, and PPV of each study and the comparison of misdiagnosis factors were calculated using Review Manager 5.3 software.

A comprehensive literature search was performed using Pubmed, PMC, MEDLINE and the Cochrane Library database. The following words and proper combinations were used: "borderline ovarian tumors" (or "low malignant potential") and "frozen section" were combined with the medical subject heading "diagnosis" ("accuracy, sensitivity, and specificity"). The search was limited to human studies and full-length reports. Studies were eligible if they exclusively investigated BOTs and had sufficient numbers to construct 3×3 tables. Studies on intra-operative FS analysis of ovarian tumors that were stratified to look at BOTs as a subgroup, or without sufficient data to construct 3×3 tables, were excluded.

Data extraction was conducted independently by two of the authors. All disagreements were resolved by discussion among all authors. For the meta-analysis, the raw and transformed data were calculated, and both fixed-effect and random-effect models were used to estimate the overall proportions. The heterogeneity was evaluated by Q test and I^2^. The pooled odds ratio (OR) and 95% confidence intervals (CI) were performed using log-transformed data with the Mantel-Haenszel method. Forest plots were used to visualize the results of the meta-analysis.

Results
=======

A total of 155 patients were identified in our retrospective study. The median age was 40 years (range13-86 years) and mean CA-125 level at the time of diagnosis was 201.6 U/ml (range1.39-4918 U/ml). Histologic subtypes included serous in 70 patients (45.2%), mucinous in 77 patients (49.7%), others in eight patients (5.1%). The mean size of tumors was 13 cm (range1.9-40.0 cm). Mucinous tumors had the largest mean size of 16.6 cm (range 1.9-40.0cm). Based on the FIGO staging system, 121 patients (78.1%) were stage I. A total of 41 patients (26.5%) had bilateral lesions.

The comparison between FS and PS diagnosis is shown in Table [1](#T1){ref-type="table"}. The overall agreement between FS and PS diagnosis was observed in 127/155 cases (81.9%), yielding a sensitivity and a positive predictive value of 92.7% and 87.6%, respectively. Of note, under-diagnosis was identified in 22 cases (14.2%), whereas over-diagnosis was identified in 6 cases (3.9%). The discrepancy in cases are as follows: in the under-diagnosis group, 15 cases were borderline through FS/ malignant through PS, and 7 cases were benign through FS/ borderline through PS. In the over-diagnosis group, 3 cases were malignant through FS/ borderline through PS, and 3 cases were borderline through FS/ benign through PS.

The relationship between patients\' clinical characteristics and misdiagnosis of FS analysis is shown in Table [2](#T2){ref-type="table"}. In a univariate analysis, tumor size (*p*=0.048) and surgery approach (*p*=0.024) were associated with misdiagnosis of FS analysis, but the patients\' age, tumor histology, tumor stage, presence of a bilateral tumor and number of frozen sections were not associated.

In our systematic literature review, 135 studies were initially identified, of which 95 were excluded because reading the titles and abstracts showed that they did not report on the association between FS and PS diagnosis. A total of 28 articles [@B6]-[@B8], [@B17]-[@B32] were excluded because BOTs were not exclusively investigated or were assessed only in subgroup analysis, or data were insufficient to construct 3×3 tables. Finally, 1,577 cases from 13 primary studies [@B9]-[@B16], [@B32]-[@B35], including our present retrospective study, met the criteria for inclusion and were analyzed. There was no disagreement between the two authors who judged the pre-selected articles. Table [3](#T3){ref-type="table"} shows that overall accuracy was observed in 1,092/1,577 (69.2%) cases, yielding a sensitivity and a PPV of 82.5% and 81.1%, respectively. Under-diagnosis and over-diagnosis were identified in 319 (20.2%) and 166 (10.5%) cases, respectively.

Seven included studies stated the factors that affect the accuracy of FS of BOTs. Characteristics of included studies for meta-analysis are shown in Table [4](#T4){ref-type="table"}. We performed a meta-analysis to validate the findings. We found that mucinous histology (*p \<* 0.0001, OR=2.03\[1.47-2.81\]) and unilateral tumors (*p*=0.001, OR=2.39\[1.41-4.06\]) were associated with the misdiagnosis of BOT, while CA-125 (*p*=0.05, OR=0.55\[0.30-1.01\]) and surgery approach (*p*=0.50, OR=1.34\[0.57-3.11\]) were not significant statistically. The outcome of the meta-analysis is shown in Figure [1](#F1){ref-type="fig"}. Measurement of tumor diameters could not be performed by meta-analysis due to different cutoff values in the included studies.

Uncertain FS diagnoses were reported for 14 patients, such as "not excluded", "not ruled out", "favor", and "at least", of which 11 patients were proven to have BOT and 3 patients were eventually proved to have a malignancy. In Table [2](#T2){ref-type="table"} and Table [5](#T5){ref-type="table"}, these 11 patients were grouped as same-diagnosis, another 3 patients were grouped as under-diagnosis. Only 2 of 11 patients with BOT had fertility sparing surgery (FSS), and the other 12 patients had radical surgery. Two patients received chemotherapy, of whom one had an advanced stage of FIGO IV and another had a carcinoma diagnosed through PS. Both of them had a good prognosis without recurrent cancer or death.

There were 28 misdiagnosed cases, including 22 cases which were under-diagnosed and 6 cases which were over-diagnosed. There were specific final diagnoses which were of extreme importance particularly in misdiagnosis cases. In our hospital, the cases of misdiagnosis due to focal carcinoma, micro-papillary and micro-invasion were 17 (60.7%), 7(25%), 4 (14.3%), respectively. In the under-diagnosed group, 15 patients were diagnosed as borderline through FS/malignant through PS. FSS were performed on 8/15 patients, all of whom were under 40 years old; and one patient finished her fertility after surgery. Malignancy recurred in 2/15 patients; one conservative surgery had been performed on one, and radical surgery had been performed on the other, who proved to be at stage FIGO II. Both of them died before the follow-up ended in October 2016. Another 3/15 patients received chemotherapy after surgery, all of whom survived without disease. A total of seven patients were diagnosed as benign through FS/ borderline through PS, four of whom received FSS; none received chemotherapy after surgery. In the over-diagnosed group, three patients were diagnosed as malignant through FS/ borderline through PS, one patient received FSS and had chemotherapy after surgery because of advanced stage of disease and invasive implants. Another patient received chemotherapy because the visible tumor was on the surface of the ovary. Three patients were diagnosed as borderline through FS/ benign through PS, all of whom were less than 40 years old and had FSS. None of them had a recurrence of cancer or death. The comparison of clinical outcomes between misdiagnosed and same diagnosed patients are shown in Table [5](#T5){ref-type="table"}. There was no statistical significance of clinical outcome such as extent of surgery (*p*=0.838), recurrence (*p*=0.586), fertility (*p*=0.560), death (*p*=0.362) between misdiagnosed and accurately diagnosed BOT patients.

Discussion
==========

The accuracy of diagnosis through FS for BOTs varies among different studies. To assess the reliability of FS diagnosis of BOTs more precisely, we performed a retrospective study as well as a meta-analysis based on available published literature. In this paper, we examined the accuracy of FS diagnosis for BOTs in a large case series, with a total of 1,577 patients enrolled. We concluded that FS analysis of BOTs has a low accuracy, sensitivity, and PPV, also under-diagnosis and over-diagnosis occur frequently.

The sensitivity and PPV in our study were relatively high among the included studies. In most studies, each specimen had one or two [@B12], [@B13], at least two [@B9], or one to seven [@B14] representative sections sampled for FS after gross inspection, and a minimum of one section per one centimeter of maximal tumor diameter was examined for PS [@B14], [@B32]. In our hospital, the number of frozen sections of mBOT, sBOT and other type BOT were 3.21, 3.27 and 3.11 sections respectively. The average number of performed FSs was 3.2 sections. Section were added if there were questionable lesions. There was no statistical significance of frozen section numbers for diagnosis accuracy between different histological type of BOT [@B36]. On the contrary, some literatures support this view of the number of FS possibly being a factor affecting the rate of accuracy [@B21], [@B26], [@B37].

Improper treatment will follow based on the misdiagnosis of FS. Especially for those young women who still want to preserve their fertility, we should make surgical decisions much more carefully. To improve the accuracy of FS in BOT patients and guide clinical treatment, we also aimed to explore the factors affecting diagnosis accuracy by FS of BOT patients. In our retrospective study, we determined that surgery approach and tumor size were associated with misdiagnosis of FS. To the authors\' knowledge, this is the first study to claim that surgery approach is conducive to misdiagnosis of BOTs through FS. Few reports have focused on the effect of surgery approach on diagnosis using FS. Another retrospective study including 354 patients concluded that laparotomy vs. laparoscopy was not statistically significant in the FS diagnosis of BOT, which does not agree with our conclusion, so we performed a meta-analysis to further validate it. In the random model, laparotomy vs. laparoscopy was not associated with misdiagnosis of FS. The discrepant results between our retrospective study and the meta-analysis may originate from the smaller study and the obvious difference of total patients in the two studies (155 vs. 354). Nevertheless, we should also attach importance on this point. Concerns about misdiagnosis with respect to implementing laparoscopy for BOTs include cyst rupture during surgery and residual lesions. According to Fauvet et al. \[38\]and Oh et al. [@B39], tumor rupture and incomplete staging were more common when using laparoscopy to resect BOTs. Currently, it is still difficult to make definitive conclusions on this matter due to the lack of clinical studies, but it reminds us that a skilled oncology specialist with sufficient experience would be most desirable when performing laparoscopic surgery on BOT patients.

The outcome of our meta-analysis shows that mucinous histology and unilateral side are related to diagnosis using FS, excluding serum CA125. The influence of the mucinous type has often been reported [@B6], [@B20], [@B26], [@B40], [@B41]. This could be explained by the characteristics of mucinous tumors, which are commonly larger than serous tumors and contain benign, borderline, and malignant components together [@B28],[@B40]. Regrettably, mucinous histology lacked statistical significance in our retrospective study, but the *p* value was nearly 0.05.

Our meta-analysis found that based on the random-effect model, unilateral vs. bilateral tumors are not related with misdiagnosis. However, we find that D.Basaran\'s study has an important influence on the heterogeneity. When this study is excluded, the I^2^ reduces obviously. We think this originates from the high misdiagnosis rate of 40% of bilateral BOTs and small sample of 44 cases in D. Basaran\'s study. Actually, there are 59 discrepancies in that study, but the author included just 44 cases who were diagnosed as having BOT through FS. The analysis method was different from other studies, which we think it is a major reason for the heterogeneity; therefore, we removed it from the meta-analysis of tumor laterality and concluded that unilateral tumors are related to the misdiagnosis using FS. Even though our findings through our retrospective study were different from our meta-analysis results, similar results were seen in some other studies; unilateral tumors were significantly more likely to be under-diagnosed [@B9], [@B42].

It was not accessible for us to perform a meta-analysis on tumor size due to the cutoff values varying from report-to-report (i.e. 8, 10, 15 and 20 cm). Several studies agree that large tumor size is related to misdiagnosis [@B14], [@B25], [@B26], [@B40]. In a study of 101 patients, Kim JH stated that tumor diameter \> 20 cm was the only factor associated with under-diagnosis [@B14]. Large masses may have only small foci of invasion in a background of predominantly borderline tumors, which may not be sampled by FS, resulting in reclassification on final pathology [@B10].

We also focused on the clinical outcomes of BOT patients that stem from misdiagnosis of FS, because there are few reports on this aspect. In a study including 61 patients with under-diagnosis, Kim K stated that the clinical outcome of under-diagnosis by FS examination is minimal in BOTs [@B33]. Furthermore, Kim JH found that among 8 under-diagnosed patients, no patient relapsed [@B14]. They both approve that the clinical outcome of misdiagnosed BOT patients was considerable. We can\'t treat these misdiagnoses lightly because a small simple size of few related studies had good prognosis. From a long time of follow-up (range10-130 months) of our retrospective study, we verified that clinical impacts of misdiagnosis by FS are minimal in BOT patients, which is in agreement with previous studies [@B14], [@B33], [@B43]. Kim K stated that under-diagnosis was associated with the extent of surgery, but not associated with treatment failure [@B33]; however, in our retrospective study, there was no statistical significance between extent of surgery and misdiagnosis. There were 60.7% (n=17/28) patients younger than 40 years old who were misdiagnosed by FS, and 15/17 patients received fertility-sparing surgery. Not only the FS diagnosis, but also the patient\'s desire to preserve fertility, would affect a surgeon\'s decision. It is widely believed that most BOT patients have a good prognosis, but a minority will have a more aggressive form of cancer and eventually die from their disease [@B1].

Pathologists are more likely to use uncertain terms on the FS diagnosis, such as "not excluded" and "not ruled out", which is confusing to surgeons to make a proper surgery decision intra-operatively. In our study, there were 14 patients reported in this way, of which 11 patients proved to have BOT, and 3 patients eventually were diagnosed with malignancies. Only 2/11 patients were performed FSS, and the other 12 patients had radical surgery. Probably the fact that most patients (8/14) were more than 40 years old and did not desire fertility explains the excessive surgery outcome, but uncertain FS diagnosis impacted the treatment for patients to some extent. It is crucial for surgeons to communicate well with pathologists to help them, offering important clinical characteristics and intra-operative information such as the tumor size, tumor laterality, and surgery approach. It is also essential for surgeons to understand the meaning of specific terms used in FS reports to properly approach the surgical management of BOTs. It is also a reasonable option to postpone definitive surgical management of BOTs until a final histological report is available.

This study had some limitations as follows. First, this is a retrospective analysis of a single-center cohort of patients with BOTs. Second, heterogeneity regarding the diagnostic criteria of BOTs may exist, due to the large span of time and areas covered by the studies included in this pooled analysis. The strength of this study is that we have increased the sample size to verify previous findings. Furthermore, this is the first meta-analysis focusing on the misdiagnosis risks. Furthermore, we have a long-time follow-up of BOT patients, which offers important information for assessing the clinical outcomes of misdiagnosed patients.

In conclusion, our study demonstrates that FS analysis of BOTs has low accuracy, sensitivity, and PPV. Our meta-analysis validates that mucinous histology and unilateral tumors are associated with misdiagnosis of BOTs using FS. We state that laparoscopic surgery would increase the misdiagnosis risk for the first time. And the misdiagnosed patients have good clinical outcomes.
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![Frost plots evaluating misdiagnosis factors. Notes: the events were defined as misdiagnosed patients of FS, total were defined as the total number of each group. A. Frost plots evaluating mucinous histology. B. Frost plots evaluating tumor laterality. C. Frost plots evaluating CA-125. D. Frost plots evaluating surgery approach.](jcav09p2817g001){#F1}

###### 

Comparison of frozen and paraffin section diagnosis for ovarian tumors (n=155)

                                      Paraffin diagnosis   Total          
  -------------------------- -------- -------------------- -------- ----- -----
  Frozen section diagnosis   Benign   0                    7        0     7
  Borderline                 3        127 ^†^              15 ^‡^   145   
  Malignant                  0        3                    0        3     
                             Total    3                    137      15    155

Note: Benign: benign ovarian tumors; Borderline: borderline ovarian tumors; Malignant: malignant ovarian tumors.

^†^: there were 11 patients uncertain-diagnosed as BOT by frozen section, and turned out to be BOT by paraffin diagnosis; ^‡^: there were 3 patients uncertain-diagnosed as BOT by frozen section and turned out to be malignant by paraffin diagnosis.

###### 

Patient characteristics and results of frozen section diagnosis (n=155)

  variables                    Frozen diagnosis compared with permanent diagnosis             
  ---------------------- ----- ---------------------------------------------------- ----- --- -------
  Ages(years)                                                                                 0.693
  \<40                   86    14                                                   69    3   
  ≥40                    69    8                                                    58    3   
  CA-125(U/ml)                                                                                0.053
  \<35                   56    13                                                   41    2   
  ≥35                    99    9                                                    86    4   
  Surgery approach                                                                            0.024
  Laparotomy             115   14                                                   99    2   
  Laparoscopy            40    8                                                    28    4   
  Cyst rupture                                                                                0.459
  Yes                    36    3                                                    32    1   
  No                     119   19                                                   95    5   
  Tumor size(cm)                                                                              0.048
  ≤10                    80    7                                                    68    5   
  \>10                   75    15                                                   59    1   
  Bilateral disease                                                                           0.280
  Yes                    41    5                                                    36    0   
  No                     114   17                                                   91    6   
  FIGO Stage                                                                                  0.783
  I                      121   17                                                   100   4   
  II-IV                  34    5                                                    27    2   
  Histology                                                                                   0.054
  Mucinous               77    16                                                   59    2   
  Other                  78    6                                                    68    4   
  Micro papillary                                                                             0.267
  yes                    10    0                                                    9     1   
  no                     145   22                                                   118   5   
  Microinvasion                                                                               0.163
  yes                    15    0                                                    15    0   
  no                     140   22                                                   112   6   
  Peritoneal washing                                                                          0.641
  yes                    4     0                                                    4     0   
  no                     151   22                                                   123   6   
  Invasive implants                                                                           0.275
  yes                    15    4                                                    11    0   
  no                     140   18                                                   116   6   
  Noninvasive implants                                                                        0.231
  yes                    15    0                                                    14    1   
  no                     140   22                                                   113   5   
  Number of FS                                                                                0.423
  ≤3                     106   17                                                   84    5   
  ≥4                     49    5                                                    43    1   

Note: \* examined by *chi*-square test, *p* value less than 0.05 was considered statistically significant; FS: frozen section

###### 

Characteristics of included studies

  Study                      country       total   TP     FP    FN    TN   A (%)   Sen (%)   PPV (%)   under   over   same
  -------------------------- ------------- ------- ------ ----- ----- ---- ------- --------- --------- ------- ------ ------
  Bozdag H et al.2016        Turkey        36      28     2     6     NA   77.8    82.4      93.3      8       0      28
  Basaran D et al.2014       Turkey        59      37     7     15    NA   62.7    71.2      84.1      18      4      37
  Song T et al.2011          Korea         354     228    40    86    NA   64.4    72.6      85.1      108     18     228
  Shih KK et al.2011         USA           120     104    16    0     NA   86.7    NA        86.7      1       15     104
  Li M et al.2009            China         73      55     10    8     NA   75.3    87.3      84.6      18      0      55
  Kim K et al.2009           South Korea   181     109    72    0     NA   60.2    NA        60.2      11      61     109
  Kim JH et al.2009          Korea         101     63     13    25    NA   62.4    71.6      82.9      32      6      63
  Wong HF et al.2007         Singapore     181     142    39    0     NA   78.5    NA        78.5      4       35     142
  Tempfer CB et al.2007      Austria       96      69     4     23    NA   71.9    75        94.5      27      0      69
  Kayikcioglu F et al.2000   Turkey        33      23     7     3     NA   69.7    88.5      76.7      7       3      23
  Houck K et al.2000         USA           140     84     10    46    NA   60      64.6      89.4      41      15     84
  Menzin AW et al.1995       USA           48      23     16    9     NA   47.9    71.9      46.9      22      3      23
  current study.2017         China         155     127    18    10    NA   81.9    92.7      87.6      22      6      127
  total                                    1577    1092   254   231   NA   69.2    82.5      81.1      319     166    1092

Note: TP: true positive; FP: false positive; TN: true negative; FN: false negative; A: agreement; Sen: sensitivity; Spe: specificity; PPV: positive predictive value; Under: under diagnosis; Over: over diagnosis; Same: same diagnosis; NA: not available.

###### 

characteristics of included studies for meta-analysis

                   histology   tumor laterality   CA-125(U/ml)   surgery approach                                                                                
  ---------------- ----------- ------------------ -------------- ------------------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  Halenur B.2016   0           9                  8              19                 N.A.   N.A.   N.A.   N.A.   7      18     1      9      N.A.   N.A.   N.A.   N.A.
  Basaran D.2014   N.A.        N.A.               N.A.           N.A.               4      6      3      31     3      17     4      19     N.A.   N.A.   N.A.   N.A.
  Song T.2011      94          123                32             105                5      28     121    200    N.A.   N.A.   N.A.   N.A.   103    181    23     47
  Shih KK.2011     5           15                 11             89                 N.A.   N.A.   N.A.   N.A.   N.A.   N.A.   N.A.   N.A.   N.A.   N.A.   N.A.   N.A.
  Kim JH.2009      9           42                 4              21                 1      3      12     60     4      21     7      42     N.A.   N.A.   N.A.   N.A.
  Houck.2000       24          23                 32             61                 9      27     47     57     N.A.   N.A.   N.A.   N.A.   N.A.   N.A.   N.A.   N.A.
  current study    18          59                 10             68                 5      36     23     91     15     41     13     86     16     99     12     28

Note: mBOT: mucinous borderline ovarian tumors; non-mBOT: non-mucinous borderline ovarian tumors; mis: misdiagnosis; same: same diagnosis; N.A.: not available.

###### 

The comparison of clinical outcome between misdiagnosis and same-diagnosis group (n=155)

  variables           Under Diagnosis (n=22)   Over Diagnosis (n=6)   Same diagnosis (n=127)   *p\**
  ------------------- ------------------------ ---------------------- ------------------------ -------
  Chemotherapy                                                                                 0.065
  Yes                 3                        2                      9                        
  No                  19                       4                      118                      
  Extent of surgery                                                                            0.838
  conservative        12                       4                      69                       
  radical             10                       2                      58                       
  Recurrence                                                                                   0.586
  Yes                 2                        0                      6                        
  No                  20                       6                      121                      
  Re-operation                                                                                 0.895
  Yes                 0                        0                      1                        
  No                  22                       6                      126                      
  Fertility                                                                                    0.560
  Yes                 1                        0                      12                       
  No                  21                       6                      115                      
  Death                                                                                        0.362
  Yes                 2                        0                      4                        
  No                  20                       6                      123                      

Note: \* examined by *chi-square* test, *p* value less than 0.05 was considered statistically significant
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